The most common side effects of<unk>  in studies were nausea, joint and chest pain, and headache. The drug also has a black-box warning for increased risk of death and arrhythmias, as it may prolong the QT interval by blocking the hERG channel. Everyone on<unk>  should have monitoring with a baseline and repeated ECGs. If a person has a QTcF of > 500 ms or a significant ventricular arrythmia,<unk>  and other QT prolonging drugs should be stopped. There is considerable controversy over the approval for the drug, as one of the largest studies to date had more deaths in the group receiving<unk>  that those receiving placebo. Ten deaths occurred in the<unk>  group out of 79, while two occurred in the placebo group, out of 81. Of the 10 deaths on<unk> , one was due to a motor vehicle accident, five were judged as due to progression of the underlying tuberculosis and three were well after the person had stopped receiving<unk> . However, there is still significant concern for the higher mortality in people treated with<unk> , leading to the recommendation to limit its use to situations where a four drug regimen cannot otherwise be constructed, limit use with other medications that prolong the QT interval, and the placement of a prominent black box warning.
Bedaquiline
Selegiline
Rasagiline
Perhexiline
Tetrabenazine
Deutetrabenazine
Butriptyline
3-Quinuclidinyl benzilate